



Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.  
Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

**PART I**  
**STATEMENT OF CONSOLIDATED UNAUDITED RESULTS**  
**FOR THE QUARTER ENDED JUNE 30, 2015**

Sl. No.	Particulars	Rs. in Lakhs			
		3 Months ended 30.06.2015	Preceding 3 months ended 31.03.2015	Corresponding 3 Months ended 30.06.2014 in the previous period	Previous year ended 31.03.2015
		UNAUDITED	UNAUDITED [Refer note 2]	UNAUDITED [Refer note 2]	AUDITED
		(1)	(2)	(3)	(4)
<b>A)</b>	<b>Continuing operations:</b>				
1	<b>Income from operations</b>				
	(a) Net Sales / Income from Operations (Net of excise duty)	25,571.46	30,782.67	24,106.12	113,202.15
	(b) Other Operating Income	1,407.19	2,795.67	1,323.52	6,382.84
	<b>Total Income from operations (net)</b>	<b>26,978.65</b>	<b>33,578.34</b>	<b>25,429.64</b>	<b>119,584.99</b>
2	<b>Expenses</b>				
	(a) Cost of material consumed	11,285.71	13,011.04	11,938.96	49,538.50
	(b) Purchases of stock-in-trade	3,421.63	2,081.52	1,717.63	7,925.20
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(2,254.59)	(375.16)	(1,358.72)	(1,415.49)
	(d) Employee benefit expenses	4,784.20	5,254.68	3,926.27	17,206.11
	(e) Depreciation and amortisation expense	1,821.77	1,947.00	1,402.46	6,403.20
	(f) Other expenses	6,041.15	6,737.23	4,890.56	23,445.38
	<b>Total expenses</b>	<b>25,099.87</b>	<b>28,656.31</b>	<b>22,517.15</b>	<b>103,102.90</b>
3	<b>Profit/(Loss) from Operations before Other Income, finance cost &amp; Exceptional Items (1-2)</b>	<b>1,878.78</b>	<b>4,922.03</b>	<b>2,912.49</b>	<b>16,482.09</b>
4	Other Income	5,925.59	534.02	1,257.03	3,856.71
5	<b>Profit/ (Loss) from ordinary activities before finance cost &amp; Exceptional Items (3+4)</b>	<b>7,804.37</b>	<b>5,456.05</b>	<b>4,169.52</b>	<b>20,338.80</b>
6	Finance costs	1,211.47	1,512.90	1,043.58	4,743.47
7	<b>Profit/(Loss) from ordinary activities after finance cost but before Exceptional Items (5-6)</b>	<b>6,592.90</b>	<b>3,943.15</b>	<b>3,125.94</b>	<b>15,595.33</b>
8	<b>Exceptional Items:</b>				
	- Exchange Fluctuation (loss) / gain (Net)	170.50	57.94	(411.18)	(1,320.87)
	- Merger and restructuring costs (Refer note 4)	(400.80)	(163.37)	-	(1,094.01)
	- Write-off/provision of assets	-	(90.00)	-	(90.00)
	- Claims on discontinued products	-	-	-	(390.84)
	- Recovery of loans & advances written off in earlier years	130.51	-	-	160.03
	- Others	-	(64.86)	-	1,998.14
9	<b>Profit / (Loss) from Ordinary Activities before tax (7+ 8)</b>	<b>6,493.11</b>	<b>3,682.85</b>	<b>2,714.76</b>	<b>14,857.78</b>
10	Tax Expense / (credit)				
	- Tax expenses on continuing operations	2,356.54	1,261.60	816.19	5,322.99
	- Tax on dividend received from subsidiaries	-	955.89	-	9,436.78
11	<b>Net Profit / (Loss) after tax (9-10)</b>	<b>4,136.57</b>	<b>1,465.36</b>	<b>1,898.57</b>	<b>98.01</b>
12	Share of Minority Interest	(49.36)	(50.28)	-	(58.60)
13	<b>Net Profit / (Loss) for the period / year from the continuing operations (11-12)</b>	<b>4,185.93</b>	<b>1,515.64</b>	<b>1,898.57</b>	<b>156.61</b>



Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.  
Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

**PART I**  
**STATEMENT OF CONSOLIDATED UNAUDITED RESULTS**  
**FOR THE QUARTER ENDED JUNE 30, 2015**

Sl. No.	Particulars	Rs. in Lakhs			
		3 Months ended 30.06.2015	Preceding 3 months ended 31.03.2015	Corresponding 3 Months ended 30.06.2014 in the previous period	Previous year ended 31.03.2015
		UNAUDITED	UNAUDITED [Refer note 2]	UNAUDITED [Refer note 2]	AUDITED
		(1)	(2)	(3)	(4)
<b>B)</b>	<b>Discontinued operations:</b>				
14	Net gain / (loss) on discontinued businesses (Refer note 8)	-	(375.90)	(225.66)	84,343.28
	<b>Net Profit / (Loss) for the period / year from discontinued operations</b>	-	<b>(375.90)</b>	<b>(225.66)</b>	<b>84,343.28</b>
<b>C)</b>	<b>Net Profit / (Loss) for the period / year from total operations (13+14)</b>	<b>4,185.93</b>	<b>1,139.74</b>	<b>1,672.91</b>	<b>84,499.89</b>
15	Paid-up Equity Share Capital (Face value of Rs.10/-each)	5,962.56	5,961.56	5,956.56	5,961.56
16	Reserves excluding revaluation reserves				108,530.61
17	<b>Earnings per share (face value of Rs. 10/- each) - not annualised</b>				
	(a) Basic EPS (Rs.)				
	i) Continuing operations	7.02	2.54	3.19	0.26
	ii) Total operations	7.02	1.91	2.81	141.85
	(b) Diluted EPS (Rs.)				
	i) Continuing operations	7.00	2.53	3.18	0.26
	ii) Total operations	7.00	1.91	2.80	141.27

**PART II**  
**SELECT INFORMATION FOR THE QUARTER ENDED JUNE 30, 2015**

		3 Months ended 30.06.2015	Preceding 3 months ended 31.03.2015	Corresponding 3 Months ended 30.06.2014 in the previous period	Previous year ended 31.03.2015
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>				
1	<b>Public shareholding :</b>				
	(a) Number of shares	<b>43,141,419</b>	<b>43,131,419</b>	<b>43,081,419</b>	<b>43,131,419</b>
	(b) Percentage of shareholding	72.35%	72.35%	72.33%	72.35%
2	<b>Promoters and Promoter group shareholding :</b>				
	(a) Pledged / Encumbered				
	- Number of shares	-	-	<b>1,876,667</b>	-
	- Percentage of shareholding (as a % of the total share holding of promoter and promoter group)	0.00%	0.00%	11.38%	0.00%
	- Percentage of shareholding (as a % of the total share capital of the Company)	0.00%	0.00%	3.15%	0.00%
	(b) Non Pledged / Non Encumbered				
	- Number of shares	<b>16,484,202</b>	<b>16,484,202</b>	<b>14,607,535</b>	<b>16,484,202</b>
	- Percentage of shareholding (as a % of the total share holding of promoter and promoter group)	100.00%	100.00%	88.62%	100.00%
	- Percentage of shareholding (as a % of the total share capital of the Company)	27.65%	27.65%	24.52%	27.65%



Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.  
 Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

**STATEMENT OF CONSOLIDATED UNAUDITED RESULTS  
 FOR THE QUARTER ENDED JUNE 30, 2015**

	Particulars	3 Months ended 30.06.2015
<b>B</b>	<b>INVESTOR COMPLAINTS</b>	
	Pending at the beginning of the quarter	0
	Received during the quarter	44
	Disposed of during the quarter	44
	Remaining unresolved at the end of the quarter	0

**Notes:**

- The above unaudited results of the Company has been reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on July 30, 2015.
- The statutory auditors have carried out limited review of the above results for the quarter ended June 30, 2015. The unaudited results for the quarter ended March 31, 2015 and June 30, 2014 were not subjected to limited review by the statutory auditors of the Company.
- The previous period's /year's figures have been regrouped/ reclassified wherever necessary to conform to the classification of the current period.
- The Board of Directors of the Company in their meeting held on September 29, 2014 had approved a Scheme of Amalgamation between the Company and Shasun Pharmaceuticals Limited ('Shasun'). Pursuant to the Scheme of Amalgamation, each equity shareholder of Shasun will be entitled to receive 5 (five) equity shares of the Company in lieu of 16 (sixteen) equity shares held in Shasun.  
  
The appointed date for the Scheme of Amalgamation is April 1, 2015. The approval for the Scheme of Amalgamation has been received from the stock exchanges, the shareholders of both the Companies, the Competition Commission of India and the Hon'ble High Court of Judicature of Madras.  
  
Approval of Foreign Investment Promotion Board and High Court of Judicature of Bombay is awaited. The matter is listed for hearing at the Hon'ble High Court of Bombay on August 14, 2015.
- The Group had entered into an agreement with GMS Holdings, ("GMS"), whereby GMS will invest USD 21.90 Million for 25.1% stake in Stelis Biopharma Private Limited ("Stelis"), the biotech arm of the Strides Group, to fund its Greenfield project. The transaction is expected to close in Q2 of 2015-16 and is subject to customary closing conditions, regulatory and corporate approvals, as may be required.
- During the quarter ended June 30, 2015, 10,000 equity shares were allotted by the Company [ under Strides Arcolab ESOP 2011 Scheme] on exercising equal number of options.
- During the quarter, the following entities have been incorporated within the Strides Group:
  - Strides Arcolab (Australia) Pty Limited incorporated on April 29, 2015
  - Strides (Australia) Pharma Pty Limited incorporated on May 19, 2015
  - Strides (Australia) IP Pty Limited incorporated on May 19, 2015
- The amounts included under B.14 above relate to the hived off Specialty products business and certain pay outs under the agreements for sale of Ascent Pharma Health which were entered into in prior years.
- Exchange fluctuation gain/loss (net) included under Exceptional Items comprises the exchange gain / loss arising on account of restatement and settlement of long term foreign currency loans and intra-group loans & advances given and gain/ loss on related derivative contracts.



Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.  
Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS  
FOR THE QUARTER ENDED JUNE 30, 2015

- 10 On May 21, 2015, the Company's wholly owned subsidiaries Strides Pharma Global Pte. Ltd., Singapore and Strides (Australia) Pharma Pty Ltd., Australia, have entered into definitive agreements with certain wholly owned subsidiaries of Aspen Pharmacare Holdings Limited (Aspen) to acquire a generic pharmaceutical business in Australia and related assets from Aspen. The acquisition is subject to customary closing conditions and regulatory approvals.
- 11 The Group's operations have been classified into two business segments viz., "Pharmaceutical business" & "Biotech business". Segment wise Revenue, Results and Capital Employed during the quarter ended June 30, 2015:

Rs. in Lakhs

Particulars	3 Months ended 30.06.2015	Preceding 3 months ended 31.03.2015	Corresponding 3 Months ended 30.06.2014 in the previous period	Previous year ended 31.03.2015
	UNAUDITED	UNAUDITED [Refer note 2]	UNAUDITED [Refer note 2]	AUDITED
<b>1 Segment Revenue</b>				
a) Pharmaceutical business	26,978.65	33,578.34	25,429.64	119,584.99
b) Biotech business	-	-	-	-
<b>Net revenue from operations</b>	<b>26,978.65</b>	<b>33,578.34</b>	<b>25,429.64</b>	<b>119,584.99</b>
<b>2 Segment results Profit/(Loss) before exceptional items, other income, tax and interest from each segment</b>				
a) Pharmaceutical business	2,473.81	5,376.60	3,121.83	17,541.82
b) Biotech business	(464.52)	(454.58)	(209.34)	(1,290.54)
<b>Total</b>	<b>2,009.29</b>	<b>4,922.02</b>	<b>2,912.49</b>	<b>16,251.28</b>
<b>Less: Unallocable Income/(expenses):</b>				
Other Income	5,925.59	534.02	1,257.03	3,856.71
Finance cost	(1,211.47)	(1,512.90)	(1,043.58)	(4,743.47)
<i>Items considered under exceptional items:</i>				
- Net gain / (loss) on discontinued operations (Refer note 8)	-	(375.90)	(225.66)	84,343.28
- Exchange (loss) / gain on long-term foreign currency loans, intra-group loans	170.50	57.94	(411.18)	(1,320.87)
- Merger and restructuring costs	(400.80)	(163.37)	-	(1,094.01)
- Write-off/provision for assets	-	(90.00)	-	(90.00)
- Reversal / (accrual) of option cost	-	(64.86)	-	1,998.14
<b>Profit before tax from continuing and discontinued operations</b>	<b>6,493.11</b>	<b>3,306.95</b>	<b>2,489.10</b>	<b>99,201.06</b>
Tax expense	2,356.54	2,217.49	816.19	14,759.77
<b>Profit before allocation to minority interest</b>	<b>4,136.57</b>	<b>1,089.46</b>	<b>1,672.91</b>	<b>84,441.29</b>
Share of profit of minority interest (net)	(49.36)	(50.28)	-	(58.60)
<b>Profit for the year / period</b>	<b>4,185.93</b>	<b>1,139.74</b>	<b>1,672.91</b>	<b>84,499.89</b>



Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.  
Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS  
FOR THE QUARTER ENDED JUNE 30, 2015

3 Capital Employed (Segment assets - Segment liabilities)

Particulars	As at 30.06.2015	As at 30.06.2014	As at 31.03.2015
a) Pharmaceutical business	140,827.45	96,397.80	126,560.29
b) Biotech business	15,924.75	13,170.50	15,699.41
c) Unallocable	(37,181.90)	66.50	(25,896.60)
<b>Total</b>	<b>119,570.30</b>	<b>109,634.80</b>	<b>116,363.10</b>

13 Information on Standalone Results :-

Rs. in Lakhs

Particulars	3 Months ended 30.06.2015	Preceding 3 months ended 31.03.2015	Corresponding 3 Months ended 30.06.2014 in the previous period	Previous year ended 31.03.2015
	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
Total Income from operations (net)	21,931.21	27,003.99	20,080.07	92,941.84
Profit before Tax	6,782.07	8,717.84	3,785.52	66,903.56
Profit after Tax	4,802.61	6,966.45	2,679.57	53,232.15

For and on behalf of the Board

Arun Kumar  
Executive Vice Chairman & Managing Director

Bangalore, July 30, 2015